These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 10529684

  • 1. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members.
    DiMichele DM, Kroner BL.
    Vox Sang; 1999; 77 Suppl 1():31-2. PubMed ID: 10529684
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy.
    Dimichele D.
    Haemophilia; 2009 Jan; 15(1):320-8. PubMed ID: 18976249
    [Abstract] [Full Text] [Related]

  • 4. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
    DiMichele D, Kroner B, Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
    Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869
    [Abstract] [Full Text] [Related]

  • 5. International immune tolerance registry, 1997 update.
    Mariani G, Kroner B.
    Vox Sang; 1999 Oct; 77 Suppl 1():25-7. PubMed ID: 10529682
    [No Abstract] [Full Text] [Related]

  • 6. Immunogenicity and immune tolerance coagulation Factors VIII and IX.
    Rup B.
    Dev Biol (Basel); 2003 Oct; 112():55-9. PubMed ID: 12762504
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the international immune tolerance registry and the North American immune tolerance registry.
    Kroner BL.
    Vox Sang; 1999 Oct; 77 Suppl 1():33-7. PubMed ID: 10529685
    [Abstract] [Full Text] [Related]

  • 8. [Improvement in anti-hemophilic preparations and its problems. 3. Treatment of hemophilia patients with inhibitors; induction of immune tolerance by a low or intermediate dose regimen].
    Iizuka A.
    Rinsho Ketsueki; 1988 May; 29(5):640-8. PubMed ID: 3145995
    [No Abstract] [Full Text] [Related]

  • 9. Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response.
    Penner JA.
    Haemophilia; 2001 Jan; 7(1):103-8. PubMed ID: 11136390
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immune tolerance: critical issues of factor dose, purity and treatment complications.
    DiMichele DM.
    Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates.
    Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I, Kaiml M, Kornhuber B.
    Vox Sang; 1999 Dec; 77 Suppl 1():3-8. PubMed ID: 10529676
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Inhibitors in haemophilia: a primer.
    DiMichele DM.
    Haemophilia; 2000 Jul; 6 Suppl 1():38-40. PubMed ID: 10982266
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.